Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients
Abroad (travel likely)RecruitingEARLY_PHASE1
Conditions
Retinitis Pigmentosa
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Beijing Tongren Hospital of Capital Medical University, Beijing, Beijing Municipality, China
Contact: Study coordinator (Yin Shen)Contact: Principal Investigator (Wenbin Wei, PhD)Contact: Principal Investigator (Laichun Lu, PhD)
Study leads
Wenbin Wei, PhD
Principal Investigator
Beijing Tongren Hospital, CMU